Haji Aghajani Mohammad, Toloui Amirmohammad, Ahmadzadeh Koohyar, Madani Neishaboori Arian, Yousefifard Mahmoud
Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Cardiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arch Acad Emerg Med. 2022 Jun 27;10(1):e51. doi: 10.22037/aaem.v10i1.1605. eCollection 2022.
Interleukins (ILs) can act as a predictive indicator of Premature Coronary Artery Disease (pCAD) and may be useful in screening of high-risk patients. However, there is no consensus on the relationship of serum levels of ILs and pCAD, yet. As a result, this study has been conducted in order to review the literature on the relationship between serum levels of different ILs and pCAD.
Medline, Scopus, Embase, and Web of Science databases were searched until December 7 2020. Two reviewers independently screened and summarized eligible articles. A meta-analysis was performed to assess the relationship of ILs and pCAD.
12 case-control articles were included. IL-6 plasma changes do happen in pCAD patients with a standardized mean difference (SMD) of 0.51 (95% CI: 0.12-0.90; p=0.010) compared with the control group. This difference was also observed when evaluating the plasma levels of IL-1 and IL-17, with an SMD of 1.42 (95% CI: 1.11-1.73; p<0.001) and 0.59 (95% CI: 0.14-1.04; p=0.011), respectively. Meanwhile, no significant difference existed in plasma levels of IL-10 (SMD=0.26; 95% CI: -0.17-0.70; p=0.236), and IL-18 (SMD=1.44; 95% CI: -0.19-3.07; p=0.083) between pCAD patients and those in the control group.
Low level of evidence showed that there may be a significant relationship between increased plasma levels of ILs and the occurrence of pCAD. As a result, prospective cohort studies with serial assessments of serum ILs during follow up period, focusing on controlling classical risk factors of pCAD and increase in level of ILs, should be conducted.
白细胞介素（ILs）可作为早发性冠状动脉疾病（pCAD）的预测指标，可能有助于筛查高危患者。然而，关于血清白细胞介素水平与早发性冠状动脉疾病之间的关系尚未达成共识。因此，开展本研究以回顾不同白细胞介素血清水平与早发性冠状动脉疾病之间关系的相关文献。
检索Medline、Scopus、Embase和Web of Science数据库至2020年12月7日。两名评审员独立筛选并总结符合条件的文章。进行荟萃分析以评估白细胞介素与早发性冠状动脉疾病的关系。
纳入12篇病例对照文章。与对照组相比，早发性冠状动脉疾病患者的IL-6血浆水平发生变化，标准化均数差（SMD）为0.51（95%CI：0.12 - 0.90；p = 0.010）。在评估IL-1和IL-17的血浆水平时也观察到这种差异，标准化均数差分别为1.42（95%CI：1.11 - 1.73；p < 0.001）和0.59（95%CI：0.14 - 1.04；p = 0.011）。同时，早发性冠状动脉疾病患者与对照组之间的IL-10（SMD = 0.26；95%CI： - 0.17 - 0.70；p = 0.236）和IL-18（SMD = 1.44；95%CI： - 0.19 - 3.07；p = 0.083）血浆水平无显著差异。
低水平证据表明，白细胞介素血浆水平升高与早发性冠状动脉疾病的发生之间可能存在显著关系。因此，应开展前瞻性队列研究，在随访期间对血清白细胞介素进行系列评估，重点关注控制早发性冠状动脉疾病的经典危险因素以及白细胞介素水平的升高。
